Key result
Activation of the endogenous CD45 promoter in human endothelial cells induced expression of EndMT genes, increased migration and collagen gel contraction, and decreased barrier integrity.
Why the study?
Previous findings showed CD45 inhibition blocked TGFbeta-induced EndMT, prompting investigation into whether CD45 directly induces EndMT downstream of TGFbeta.
Does CD45 activation induce Endothelial-to-Mesenchymal Transition in human endothelial cells?
Does CD45 activation induce Endothelial-to-Mesenchymal Transition in human endothelial cells?
CD45 is sufficient to initiate an Endothelial-to-Mesenchymal Transition phenotype in human endothelial cells, suggesting a novel signaling role in tissue remodeling.
BACKGROUND: Endothelial-to-mesenchymal transition (EndMT) is a dynamic process in which endothelial cells acquire mesenchymal properties and in turn contribute to tissue remodeling and growth. Previously, we found EndMT associated with mitral valve adaptation after myocardial infarction. Furthermore, mitral valve endothelial cells collected at 6 months post-myocardial infarction expressed the pan-leukocyte marker CD45 and EndMT markers. Additionally, mitral valve endothelial cells induced to undergo EndMT with TGF (transforming growth factor)-β1 strongly coexpressed CD45 but not CD11b or CD14. Pharmacologic inhibition of the CD45 PTPase (protein tyrosine phosphatase) domain in mitral valve endothelial cells blocked TGFβ-induced EndMT. This prompted us to speculate that, downstream of TGFβ, CD45 induces EndMT. METHODS: We activated the endogenous CD45 promoter in human endothelial colony forming cells (ECFCs) using CRISPR (cluster regularly interspaced short palindromic repeats)/inactive Cas9 (CRISPR-associated protein 9) transcriptional activation. Bulk RNA sequencing was performed on control ECFCs and CD45-positive ECFCs to identify transcriptomic changes. Three functional assays-cellular migration, collagen gel contraction, and transendothelial electrical resistance-were conducted to assess mesenchymal properties in CD45-positive ECFCs. RESULTS: Activation of the endogenous CD45 promoter in ECFC and 3 additional sources of endothelial cells induced expression of several genes implicated in EndMT. In addition, CD45-positive ECFCs showed increased migration, a hallmark of EndMT, increased collagen gel contraction, a hallmark of mesenchymal cells, and decreased cell-cell barrier integrity, indicating reduced endothelial function. CONCLUSIONS: CD45 is sufficient to incite an EndMT phenotype and acquisition of mesenchymal cell properties in normal human ECFCs. We speculate that CD45, through its C-terminal PTPase domain, initiates signaling events that drive EndMT.
No takes yet. Share an insight, caveat, or question.
Nasim et al. (2023) studied Endothelial-to-Mesenchymal Transition. Activation of endogenous CD45 promoter using CRISPR/inactive Cas9 vs. Control endothelial colony forming cells was evaluated on Transcriptomic changes and mesenchymal properties (cellular migration, collagen gel contraction, transendothelial electrical resistance). Activation of the endogenous CD45 promoter in human endothelial cells induced expression of EndMT genes, increased migration and collagen gel contraction, and decreased barrier integrity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: